EUVIMEDEUVIMED entdecken
Crossref

Clinicopathological spectrum of CD10 , BCL6 , MUM1 triple‐positive diffuse large B‐cell lymphoma and large B‐cell lymphoma with IRF4 rearrangement

Sei Na iD, Ki Rim Lee iD, Yoon Kyung Jeon iD, Hyungjin Kim iD, Jeong-Ok Lee iD, Ji Yun Lee iD, Sang-A Kim iD, Hongseok Yun iD, Jin Ho Paik iD

Histopathology · 2026

DOI: 10.1111/his.70169 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Sei Na und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Interferon Regulatory Factors, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: National Research Foundation of Korea funded by ministry of Science and ICT, Korea, Seoul National University Bundang Hospital, Ministry of Science and ICT, South Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Triple‐positive diffuse large B‐cell lymphoma ( TP ‐ DLBCL ), co‐expressing CD10 , BCL6 and MUM1 , represents a rare subset with potential associations with IRF4 rearrangements. This study investigated the clinicopathological spectrum and frequency of IRF4 rearrangements in TP ‐ DLBCL and characterised large B‐cell lymphoma with IRF4 rearrangement ( LBCL ‐ IRF4 ‐R) in a Korean population. Methods and results We retrospectively analysed 977 DLBCL cases diagnosed between 2003 and 2022. TP‐DLBCL accounted for 4.9% (48/977) of all cases. Among 40 eligible TP‐DLBCL cases, 17.5% (7/40) harboured IRF4 rearrangements by fluorescence in situ hybridization. Including two double‐positive cases, nine LBCL‐ IRF4 ‐R cases were characterized. TP‐DLBCL showed a significant predilection for low‐stage disease (stage I–II: 30/40, 75.0%) compared to non‐TP‐DLBCL (67/143, 46.9%; P = 0.002). LBCL‐ IRF4 ‐R patients were significantly younger than TP‐DLBCL without IRF4 rearrangement (mean age 40.6 versus 59.8 years, P = 0.049) with distinct features including preferential involvement of lymph nodes, tonsils and spleen (6/9, 66.7%), less frequent multiple extranodal involvement ( P = 0.041) and conglomerated mass presentation. Most LBCL‐ IRF4 ‐R cases achieved complete remission, though one adult case with MYD88 mutation showed aggressive behaviour. Genetic profiling revealed heterogeneous patterns with IRF4 mutations in all sequenced cases, and recurrent PIM1 , HIST1H1E and CARD11 mutations.

Conclusions

LBCL‐ IRF4 ‐R represents a clinically and molecularly heterogeneous entity extending beyond paediatric populations and head‐and‐neck locations. IRF4 fluorescence in situ hybridization testing should be considered in TP‐DLBCL cases, particularly in younger patients with localized disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon Regulatory FactorsLymphoma, Large B-Cell, DiffuseHumansInterferon Regulatory Factor-4Proto-Oncogene Proteins c-bcl-6FemaleMiddle AgedMaleRetrospective StudiesGene RearrangementAgedAdultNeprilysinAged, 80 and overIn Situ Hybridization, FluorescenceBiomarkers, TumorYoung AdultAdolescent

Stichwörter der Autor:innen

Immunophenotypingchromosome aberrationsinterferon regulatory factor‐4lymphoma, large B‐cell, diffuseprognosisyoung adult

Substanzen

Interferon Regulatory FactorsInterferon Regulatory Factor-4Proto-Oncogene Proteins c-bcl-6BCL6 protein, humanNeprilysinBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Pathology, Seoul National University Hospital, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Genomic Medicine, Seoul National University Hospital, Seoul, Korea.

ORCID-Profile: Sei Na, Ki Rim Lee, Yoon Kyung Jeon, Hyungjin Kim, Jeong-Ok Lee, Ji Yun Lee, Sang-A Kim, Hongseok Yun, Jin Ho Paik

Förderung

  • National Research Foundation of Korea funded by ministry of Science and ICT, Korea
  • Seoul National University Bundang Hospital
  • Ministry of Science and ICT, South Korea

Zitieren

APA

Na, S., Lee, K. R., Jeon, Y. K., Kim, H., Lee, J. O., Lee, J. Y., Kim, S. A., Yun, H., & Paik, J. H. (2026). Clinicopathological spectrum of CD10 , BCL6 , MUM1 triple‐positive diffuse large B‐cell lymphoma and large B‐cell lymphoma with IRF4 rearrangement. Histopathology. https://doi.org/10.1111/his.70169

Vancouver

Na S, Lee KR, Jeon YK, Kim H, Lee JO, Lee JY, et al. Clinicopathological spectrum of CD10 , BCL6 , MUM1 triple‐positive diffuse large B‐cell lymphoma and large B‐cell lymphoma with IRF4 rearrangement. Histopathology. 2026. doi:10.1111/his.70169

BibTeX
@article{Na2026,
  author = {Na, Sei and Lee, Ki Rim and Jeon, Yoon Kyung and Kim, Hyungjin and Lee, Jeong-Ok and Lee, Ji Yun and Kim, Sang-A and Yun, Hongseok and Paik, Jin Ho},
  title = {Clinicopathological spectrum of CD10 , BCL6 , MUM1 triple‐positive diffuse large B‐cell lymphoma and large B‐cell lymphoma with IRF4 rearrangement},
  journal = {Histopathology},
  year = {2026},
  doi = {10.1111/his.70169}
}
Kostenlos starten →